Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder

Buprenorphine/samidorphan (BUP/SAM; ALKS 5461) is an investigational opioid system modulator for the adjunctive treatment of patients with major depressive disorder (MDD), who did not respond adequately to prior antidepressant therapy (ADT). FORWARD-2, an open-label extension study, assessed long-te...

Descripción completa

Detalles Bibliográficos
Autores principales: Thase, Michael E., Stanford, Arielle D., Memisoglu, Asli, Martin, William, Claxton, Amy, Bodkin, J. Alexander, Trivedi, Madhukar H., Fava, Maurizio, Yu, Miao, Pathak, Sanjeev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6897901/
https://www.ncbi.nlm.nih.gov/pubmed/31254971
http://dx.doi.org/10.1038/s41386-019-0451-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6897901/
https://www.ncbi.nlm.nih.gov/pubmed/31254971
http://dx.doi.org/10.1038/s41386-019-0451-3

Ejemplares similares